

RESULTS OF NANOFORM COLLABORATIVE STUDY TO BE PRESENTED AT THE 2025 PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY (PODD) SUMMIT

Nanoform Finland Plc | Press Release | October 21, 2025 at 09:00:00 EEST

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two proof-of-concept studies conducted in collaboration between Nanoform and Takeda will be presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) conference in Boston, Mass., which takes place on October 27-28, 2025. The presentation will take place on day 1, in track 1 of the event, from 12.10 – 12.30 p.m. EDT.

The presentation, titled *“Delivering Value for Patients Through Nanoforming in Plasma Derived Therapies,”* will include the results of studies that have employed Nanoform’s technology to enable alternative routes of administration of biologic treatments, with the first focused on high concentration suspension enabled formulations for subcutaneous (SC) injections, and the second on formulation of an inhaled dry-powder biologic.

The first proof-of-concept study evaluated the suitability of nanoformed high-concentration biologics formulations for subcutaneous delivery. Nanoform’s patented biologics platform was demonstrated to achieve high protein concentrations in suspension formulations with acceptable syringeability, enabling SC delivery together with its advantages of convenience and relative ease of administration.

The second non-clinical proof-of-concept study investigated nanoformed Alpha-1 antitrypsin (A1AT) in the treatment of Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder linked to emphysema and other lung diseases. AAT deficiency is typically treated with weekly IV infusions of plasma-derived AAT, which can be inconvenient for patients. Results suggest the nanoformed A1AT therapy, which leverages Nanoform’s novel solidification platform, could be a promising targeted therapeutic approach delivered via dry-powder inhalation.

On day 2 of the PODD summit from 4.05 – 4.35 p.m. EDT, Nanoform’s Sergie Letser, Deputy Chief Commercial Officer and Senior Vice President of Business Development for the U.S, is to participate in a panel discussion titled, *“Challenges and Opportunities in Delivering Hyperconcentrated Formulations.”* Moderated by Dr. Stephanie Reed, Director, Early-Stage Formulation, Biopharmaceutical Development, AstraZeneca, and featuring representatives from Teva, Kymanox and Pfizer, the panel will consider novel device approaches and strategies to overcome drug delivery challenges of aggregation, precipitation, opalescence, particle formation, and high viscosity. PODD 2025 takes place at the Westin Copley Place hotel, Boston. For more information on the summit visit: nanoform.com/events, and to arrange a meeting with Sergie Letser at the event, contact Christian Jones using the details below.

For further information, please contact:

Christian Jones, Chief Commercial Officer

christian.jones@nanoform.com

+44 (0)7804 474 771

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com

+46 (0)7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.

Attachments

Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit